Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cog-Plus
- Development stage
- Unknown
- Lead developer
- Ind Blues Pharma
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Cog-Plus (COG PLUS) is a fixed-dose combination tablet developed and marketed by Ind Blues Pharma. It contains five active ingredients: betahistine (16 mg), cholecalciferol (Vitamin D3, 400 IU), ginkgo biloba extract (60 mg), piracetam (400 mg), and vinpocetine (5 mg). This combination is formulated to provide neurovascular and vestibular support, and is primarily indicated for the management of vertigo, Meniere's disease, age-related memory impairment, tinnitus, cerebral circulatory disorders, and cognitive dysfunction or vascular dementia. Betahistine improves microcirculation in the inner ear to control vertigo; piracetam and vinpocetine enhance cerebral blood flow, neuroplasticity, and cognitive performance; ginkgo biloba provides neuroprotective and antioxidant effects; and cholecalciferol supports nervous system function and neuro-immune modulation.
- Brand names
- Cog-Plus
- Other names
- betahistine + cholecalciferol + ginkgo biloba + piracetam + vinpocetinebetahistine + vitamin D3 + ginkgo biloba + piracetam + vinpocetine
02
Targets
AMPAR (AMPA receptor)HRH1 (Histamine H1 Receptor)HRH3 (Histamine Receptor H3)PDE1 (Phosphodiesterase 1)PTAFR (Platelet-activating factor receptor)NaV (Voltage-gated sodium channels)VDR (Vitamin D receptor)
Beyond the preview
Go deeper on Cog-Plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cog-Plus.